Related Experiment Video
Updated: Mar 6, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation, atrial fibrillation, and chronic kidney disease-whose side are you on?
Gunnar Henrik Heine1, Vincent Brandenburg2
1Saarland University Medical Center, Saarland University Faculty of Medicine, Internal Medicine IV-Nephrology and Hypertension, Homburg, Germany.
Insights
Oral anticoagulants in advanced chronic kidney disease patients with atrial fibrillation did not prevent strokes or cause bleeding but did prolong life. Further randomized trials are needed to clarify optimal treatment strategies.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation management in advanced chronic kidney disease (CKD) is challenging.
- Evidence for oral anticoagulant therapy (OAT) in this population is limited and controversial.
- Observational studies provide conflicting results regarding OAT efficacy and safety in CKD patients.
Purpose of the Study:
- To investigate the effects of OAT on ischemic stroke, hemorrhage, and survival in elderly patients with advanced CKD and atrial fibrillation.
- To evaluate the real-world outcomes of OAT in a specific high-risk patient cohort.
Main Methods:
- Retrospective analysis of a Canadian health care system database.
- Inclusion of elderly patients with advanced CKD and atrial fibrillation.
- Comparison of outcomes between patients receiving OAT and those not receiving OAT.
Main Results:
- OAT did not significantly reduce the incidence of ischemic strokes.
- OAT was associated with an increased risk of induced hemorrhages.
- OAT demonstrated a survival benefit, prolonging life in the studied population.
Conclusions:
- The findings present a paradoxical effect of OAT in advanced CKD patients with atrial fibrillation.
- The results highlight the urgent need for robust, randomized controlled trials to establish definitive guidelines.
- Further research is crucial to balance the risks and benefits of OAT in this complex patient group.
Abstract:
Whether to initiate oral anticoagulant therapy in advanced chronic kidney disease patients with atrial fibrillation remains debatable. Although randomized trial data are lacking, observational studies yield controversial results. Keskar and colleagues analyzed data from a Canadian health care system and found that in elderly chronic kidney disease patients with atrial fibrillation, oral anticoagulant therapy did not prevent ischemic strokes, induced hemorrhages, but prolonged life. These paradoxical findings emphasize the dire need for an adequately powered randomized trial.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Kidney Injury V: Interprofessional Care

